Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2022-11-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Samil Pharmaceutical Co., Ltd. for the third quarter of 2022 (제 70 기 3분기). It contains detailed financial statements, business descriptions, management analysis, and governance information, which are characteristic of an interim financial report. It is not a mere announcement or certification, as it provides substantive financial data and operational details. 9M 2022
2022-11-14 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Samil Pharmaceutical regarding the adjustment of the exchange price for convertible bonds (specifically the 20th series of bearer non-guaranteed private exchangeable bonds). It details the change in the exchange price due to market price fluctuations, which affects the company's capital structure and potential share dilution. This type of disclosure regarding changes to convertible securities or capital instruments falls under the 'Capital/Financing Update' category.
2022-10-28 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on the Termination of a Trust Agreement' (신탁계약해지결과보고서) filed by Samil Pharmaceutical Co., Ltd. with the Financial Supervisory Service (FSS) of South Korea. It details the termination of a trust contract used for share buybacks, including the contract amount, the number of shares acquired, and the resulting status of treasury shares. This type of filing is a standard regulatory disclosure regarding share repurchase activities and their conclusion, which falls under the category of 'Transaction in Own Shares' (POS).
2022-10-06 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Exchange regarding the termination of a trust contract for the acquisition of treasury shares (자기주식취득 신탁계약 해지 결정). This falls under the category of company transactions involving its own shares, specifically share repurchase/buyback related activities. According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct classification for reports of a company buying back or selling its own shares.
2022-10-04 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from Samil Pharmaceutical regarding the adjustment of the exercise price for its outstanding bond with warrants (BW). It details the change in the exercise price due to market price fluctuations, which is a standard capital structure update. This type of filing is categorized as a Capital/Financing Update (CAP) as it directly relates to the terms of the company's debt instruments and potential equity dilution.
2022-09-15 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Semi-Annual Report' (반기보고서) for Samil Pharmaceutical Co., Ltd. for the period ending June 30, 2022. It contains comprehensive financial statements, business descriptions, management analysis, and governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.